Synergy Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--

Synergy Pharmaceuticals Inc. SGYP today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Morgan Stanley Global Healthcare Conference on Friday, September 18th, 2015 at 9:20 a.m. Eastern Time at the Grand Hyatt New York.

A live webcast of the presentation will be accessible through the Investor Relations section of the company's website at www.synergypharma.com. A replay of the webcast will be available on Synergy's website for 60 days following the conference.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of novel therapies for the treatment of gastrointestinal (GI) diseases and disorders. Synergy's proprietary GI platform is based on uroguanylin, a naturally occurring human peptide and key regulator of normal GI activity. Plecanatide is our lead uroguanylin analog currently in late-stage clinical development for chronic idiopathic constipation and irritable bowel syndrome with constipation. Dolcanatide (SP-333) is our next-generation uroguanylin analog presently being explored for ulcerative colitis. For more information, please visit www.synergypharma.com .

Synergy Pharmaceuticals Inc.
Gem Gokmen Hopkins, 212-584-7610
V.P., Investor Relations and Corporate Communications
ggokmen@synergypharma.com

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!